Department of Medical Sciences, University of Turin, 10126 Turin, Italy.
Pathology Unit, AOU City of Health and Science of Turin, 10126 Turin, Italy.
Int J Med Sci. 2021 Jan 26;18(6):1406-1414. doi: 10.7150/ijms.52688. eCollection 2021.
Enolase (ENO) 1 is a key glycolytic enzyme and important player in tumorigenesis. ENO1 overexpression has been correlated with tumor progression and/or worse prognosis in several solid malignancies. However, data concerning the impact of ENO1 in cancer conflict. The study correlated local and circulating ENO1 protein levels in esophageal cancer (EC) with clinicopathological data, to assess its potential clinical value. ENO1 expression was analyzed by immunohistochemistry in paired tumor and non-tumor tissue samples from 40 EC cases and mucosal biopsies from 45 Barrett's esophagus (BE) cases, plus in plasma from these patients and 25 matched healthy controls. ENO1 was abnormally elevated in cancer-cell cytoplasm in both EC types, in esophageal squamous cell carcinoma and in adenocarcinoma (EAC), increasing significantly with tumor stage progression and the transition from BE to EAC. EAC patients exhibited significantly lower ENO1 plasma concentrations than normal subjects. Neither local nor systemic ENO1 expression levels were significantly associated with overall survival. These results indicate ENO1 as potential biomarker, delineating a population of patients with Barrett's esophagus at high risk of cancer, and as new therapeutic opportunity in EC patient management. However, further confirmation might be necessary.
烯醇化酶（ENO）1 是一种关键的糖酵解酶，也是肿瘤发生的重要参与者。ENO1 的过表达与几种实体恶性肿瘤的肿瘤进展和/或预后不良相关。然而，ENO1 在癌症中的影响的数据存在冲突。本研究通过免疫组织化学分析了 40 例食管癌（EC）患者配对的肿瘤和非肿瘤组织样本以及 45 例巴雷特食管（BE）患者的黏膜活检样本中局部和循环 ENO1 蛋白水平，并分析了这些患者和 25 名匹配的健康对照者的血浆。ENO1 在两种类型的癌症细胞细胞质中均异常升高，在食管鳞状细胞癌和腺癌（EAC）中，随着肿瘤分期的进展和从 BE 到 EAC 的转变而显著增加。EAC 患者的 ENO1 血浆浓度明显低于正常对照者。局部和全身 ENO1 表达水平与总生存期均无显著相关性。这些结果表明 ENO1 是一种潜在的生物标志物，可区分具有高癌症风险的巴雷特食管患者群体，并为 EC 患者管理提供新的治疗机会。然而，可能需要进一步的确认。
